ClinicalTrials.gg
CompletedNCT02723773Updated Dec 12, 2025Results posted

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 161 sites in 18 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,539
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
6th of 46
7,539 · median 239
Started
2016
with 2 others
Phase 3
22 of 46
2 open now
Registered
18th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 18th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of older adults.

Read the detailed description

This is the long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults.

03

Conditions studied

  • Herpes Zoster
  • Herpes Zoster Vaccine

Browse trials for

Keywords

  • Efficacy
  • Immunogenicity
  • Safety
  • Adults
  • Herpes zoster
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, ability to have scheduled contacts to allow evaluation during the study). Or subjects with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, availability for follow-up contacts).
  • Written obtained from the subject prior to performance of any study specific procedure.
  • Subject who participated in ZOSTER-006 or ZOSTER-022 studies and received at least one dose of HZ/su vaccine.

Additional inclusion criteria for the 1-Additional Dose Revaccination and Control groups, ONLY:

  • Female subjects of non- may be enrolled in this study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in this study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (pharmaceutical product or device) at the time of enrolment or planned use during the study period.
  • Previous vaccination against Varicella Zoster Virus (VZV) or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than the HZ/su vaccine administered in studies ZOSTER-006/022).
  • Chronic administration (defined as ≥ 14 consecutive days in total) of or other immune-modifying drugs during the period starting six months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study period. For , this will mean prednisone ≥ 20 mg/day or equivalent. A prednisone dose of \< 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration of long-acting immune-modifying drugs (e.g., infliximab, rituximab) within 6 months prior to Visit Month 0 of study ZOSTER-049 or expected administration at any time during the study period.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • Administration of immunoglobulins and/or any blood products within 3 months prior to Visit Month 0 of study ZOSTER-049 or planned administration during the study period.
  • Prolonged use (> 14 consecutive days) of oral and/or parenteral antiviral agents that are active against VZV (acyclovir, valacyclovir, famciclovir, etc. ) and planned to be used during the study period for an indication other than to treat suspected or confirmed HZ or an HZ-related complication (topical use of these antiviral agents is allowed).
  • Important underlying illness that in the opinion of the investigator would be expected to interfere significantly during the study.

Additional exclusion criteria for the 1-Additional Dose Revaccination and Control groups, only:

  • Subjects who experienced an SAE from first vaccination in the previous ZOSTER-006/022 studies to enrolment in study ZOSTER-049 that was considered related to study vaccine by either the investigator or the sponsor.
  • Subjects with a new onset of a pIMD or exacerbation of a pIMD from first vaccination in the previous ZOSTER-006/022 studies to enrolment in study ZOSTER-049.
  • Use of any investigational or non-registered product (pharmaceutical product or device) within 30 days preceding the first dose of study vaccine or planned use during the study period.
  • Administration or planned administration of any other immunizations within 30 days before the first study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines (i.e., inactivated and subunit vaccines, including inactivated and subunit influenza vaccines for seasonal or pandemic flu, with or without adjuvant) may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation (such as materials that may possibly contain latex-gloves, syringes, etc.). Please note, the vaccine and vials in this study do not contain latex.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions (if of ).
  • Previous episode/history of HZ.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
7,539 participants (actual)

Study arms

  • No intervention
    LTFU Group

    Participants who received at least 1 dose of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the current ZOSTER-049:EXT 006-022 study were followed up for long-term vaccine efficacy and safety.

  • Experimental
    1-Additional Dose Group

    Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies received 1 additional dose of the HZ/su vaccine at Month 0 in the current ZOSTER-049:EXT 006-022 study.

    Biological: Herpes Zoster Vaccine GSK1437173A

  • Experimental
    Revaccination Group

    Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies were revaccinated with 2 additional doses of the HZ/su vaccine at Month 0 and Month 2 in the current ZOSTER-049:EXT 006-022 study.

    Biological: Herpes Zoster Vaccine GSK1437173A

  • No intervention
    Control Group

    Participants who received 2 doses of the HZ/su vaccine in the ZOSTER-006/022 primary studies and no additional doses of the HZ/su vaccine in the current ZOSTER-049:EXT 006-022 study, but who served as a control for the 2 groups that received 1 or 2 additional doses (1-Additional Dose Group and Revaccination Group).

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall

    A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by Polymerase Chain Reaction (PCR) and/or by HZ Ascertainment Committee (HZAC) determination, as per the algorithm pre-specified in the protocol. As pre-specified in the protocol: * due to the high VE observed in ZOSTER-006/022 studies, recipients of placebo in both studies were offered cross-vaccination with HZ/su. Since there was no placebo group in this study, historic controls were used for VE assessment. Incidence rates estimations on Historical Control group were done by utilizing Poisson regression model using placebo data from ZOSTER-006/022 studies to obtain the coefficients by age ranges. * the participants in Control group were a subset of LTFU group that were randomized to serve as control for those who were vaccinated in this study, otherwise they were treated similarly as LTFU group, hence LTFU and Control groups were combined.

    Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)

Secondary outcomes

  1. Number of Participants Having at Least One Confirmed HZ Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, by Age Ranges

    A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)

  2. Number of Participants Having at Least One Confirmed HZ Case From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

    A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. As pre-specified in the protocol: \- participants from the Placebo groups in the ZOSTER-006/022 studies for Year 1 through Year 4 preceding the ZOSTER-049 EXT:006-022 study start and from the hypothetical Historical control group in the ZOSTER-049:EXT 006-022 study for Year 6 and onwards were combined in the Placebo/Historical control group.

    Time frame: From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years

  3. Number of Participants Having at Least One Confirmed HZ Case Over the Follow-up Years From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

    A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. Confirmed HZ cases data was not collected for the participants included in the HZ/su and Placebo/Historical control groups during Year 5, as this was a gap year between end of ZOSTER-006/-022 studies and start of ZOSTER-049:EXT-006-022 study. Results from the ZOSTER-006/022 studies were pooled for each year after vaccination with methods used in these studies. For overlapping years between ZOSTER-006/022 studies and this study, all the data were pooled. For the non-overlapping years only the data from ZOSTER-049:EXT 006-022 study was used.

    Time frame: Over the follow-up years (Year 1, Year 2, Year 3, Year 4, Year 6, Year 7, Year 8, Year 9, Year 10 and Year 11) from one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72)

  4. Number of Participants Having at Least One Post-herpetic Neuralgia (PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

    PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)

  5. Number of Participants Having at Least One PHN Case From One Month Post-Dose 2 in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

    PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years

  6. Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

    HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)

  7. Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case From One Month Post-dose 2 (Month 3) in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

    HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years

  8. Anti-glycoprotein (gE) Antibody Concentrations for Humoral Immunity (HI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group

    Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies

  9. Frequency of Antigen-specific CD4 (2+) T-cells for Cell Mediated Immunity (CMI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group

    Frequency of CD4 (2+) T-cells with antigen-specific Interferon gamma (IFN-γ) and/or Interleukin-2 (IL-2) and/or Tumour Necrosis Factor alpha (TNF-α) and/or CD40 Ligand (CD40L) secretion/expression to gE was determined by Intracellular Cytokine Staining (ICS) and expressed in CD4 (2+) T-cells/million cells. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

    Time frame: At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies

  10. Anti-gE Antibody Concentrations for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies

    Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

    Time frame: At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies

  11. Frequency of Antigen-specific CD4 (2+) T-cells for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9 and 10 After the Primary Vaccination in ZOSTER-006/022 Studies

    Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

    Time frame: At Years 5, 6, 7, 8, 9, and 10 after the primary vaccination in ZOSTER-006/022 studies

  12. Anti-gE Antibody Concentrations for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study

    Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

    Time frame: At Month 1 in the current ZOSTER-049:EXT 006-022 study

  13. Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study

    Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

    Time frame: At Month 1 in the current ZOSTER-049:EXT 006-022 study

  14. Anti-gE Antibody Concentrations for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study

    Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

    Time frame: At Month 3 in the current ZOSTER-049:EXT 006-022 study

  15. Frequency of Antigen-specific CD4 (2+) T-cells for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study

    Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

    Time frame: At Month 3 in the current ZOSTER-049:EXT 006-022 study

  16. Anti-gE Antibody Concentrations for 1 Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study

    Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

    Time frame: At Month 0 and Years 1, 2, 3, 4, 5 and 6 in the current ZOSTER-049:EXT 006-022 study

  17. Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study

    Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

    Time frame: At Month 0 and Years 1, 2, 3, 4, 5 and 6 in the current ZOSTER-049:EXT 006-022 study

  18. Number of Participants With Any and Grade 3 Solicited Local Symptoms

    The assessed solicited local symptoms included pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study

  19. Duration in Days of Solicited Local Symptoms

    Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited local symptoms included pain, redness and swelling.

    Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study

  20. Number of Participants With Any, Grade 3 and Related Solicited General Symptoms

    The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5 degrees Celsius (°C)\], gastrointestinal symptoms, headache, myalgia, and shivering. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \>39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study

  21. Duration in Days of Solicited General Symptoms

    Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5°C\], gastrointestinal symptoms, headache, myalgia, and shivering.

    Time frame: Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study

  22. Number of Participants With Any Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: Within 30 days after any vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study

  23. Number of Participants With Any and Related Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to vaccination.

    Time frame: From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month 0 until 12 months after last HZ/su vaccination (Revaccination group)

  24. Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: During the total duration of ZOSTER-049:EXT 006-022 study (from Month 0 to Month 72)

  25. Number of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)

    pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any pIMDs = occurrence of a pIMD regardless of relation to vaccination. Related pIMD = a pIMD assessed by the investigator as related to the study vaccination.

    Time frame: From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month until 12 months after last HZ/su vaccination (Revaccination group)

07

Results

Posted Sep 19, 2024

Participant flow

Potentially eligible participants who participated and received at least one dose of the HZ/su vaccine in the ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies were contacted and considered for entry in the current ZOSTER-049:EXT 006-022 (NCT02723773) study.

Participant flow — Overall Study
MilestoneLTFU Group1-Additional Dose GroupRevaccination GroupControl Group
Started72896160119
Completed5570525197
Not completed17199922
Withdrew: Adverse event934319
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject3605610
Withdrew: Migrated/moved from study area37001
Withdrew: Lost to follow-up198000
Withdrew: Other189122

Outcome measures

PrimaryNumber of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall

A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by Polymerase Chain Reaction (PCR) and/or by HZ Ascertainment Committee (HZAC) determination, as per the algorithm pre-specified in the protocol. As pre-specified in the protocol: * due to the high VE observed in ZOSTER-006/022 studies, recipients of placebo in both studies were offered cross-vaccination with HZ/su. Since there was no placebo group in this study, historic controls were used for VE assessment. Incidence rates estimations on Historical Control group were done by utilizing Poisson regression model using placebo data from ZOSTER-006/022 studies to obtain the coefficients by age ranges. * the participants in Control group were a subset of LTFU group that were randomized to serve as control for those who were vaccinated in this study, otherwise they were treated similarly as LTFU group, hence LTFU and Control groups were combined.

Time frame:
During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Reported as:
Count of participants · Participants
Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall
ParticipantsLTFU+Control >=50YOA GroupHistorical Control >=50 YOA Group
Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall69341
Statistical analysis
  • LTFU+Control >=50YOA Group vs Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 79.77 · 95% CI 73.72 to 84.61VE=1 - the relative risk (RR). RR=the ratio of the incidence rates of LTFU+Control \>=50YOA Group over Historical Control \>=50YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One Confirmed HZ Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, by Age Ranges

A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Reported as:
Count of participants · Participants
Number of Participants Having at Least One Confirmed HZ Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, by Age Ranges
ParticipantsLTFU+Control 50-59 YOA GroupLTFU+Control 60-69 YOA GroupLTFU+Control >=60 YOA GroupLTFU+Control >=70 YOA GroupHistorical Control 50-59 YOA GroupHistorical Control 60-69 YOA GroupHistorical Control >=60 YOA GroupHistorical Control >=70 YOA Group
Number of Participants Having at Least One Confirmed HZ Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, by Age Ranges12957489070249179
Statistical analysis
  • LTFU+Control 50-59 YOA Group vs Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 86.67 · 95% CI 75.55 to 93.36VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control 50-59 YOA Group over Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • LTFU+Control 60-69 YOA Group vs Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 87.14 · 95% CI 74.17 to 94.35VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control 60-69 YOA Group over Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • LTFU+Control >=60 YOA Group vs Historical Control >=60 YOA Group · Poisson regression method · Vaccine efficacy: 77.11 · 95% CI 69.37 to 83.14VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control \>=60 YOA Group over Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • LTFU+Control >=70 YOA Group vs Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 73.18 · 95% CI 62.94 to 80.92VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control \>=70 YOA Group over Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One Confirmed HZ Case From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. As pre-specified in the protocol: \- participants from the Placebo groups in the ZOSTER-006/022 studies for Year 1 through Year 4 preceding the ZOSTER-049 EXT:006-022 study start and from the hypothetical Historical control group in the ZOSTER-049:EXT 006-022 study for Year 6 and onwards were combined in the Placebo/Historical control group.

Time frame:
From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years
Reported as:
Count of participants · Participants
Number of Participants Having at Least One Confirmed HZ Case From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
ParticipantsHZ/su >=50 YOA GroupHZ/su 50-59 YOA GroupHZ/su 60-69 YOA GroupHZ/su >=60 YOA GroupHZ/su >=70 YOA GroupPlacebo/Historical Control >=50 YOA GroupPlacebo/Historical Control 50-59 YOA GroupPlacebo/Historical Control 60-69 YOA GroupPlacebo/Historical Control >= 60 YOA GroupPlacebo/Historical Control >=70 YOA Group
Number of Participants Having at Least One Confirmed HZ Case From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges10116128573818193160623463
Statistical analysis
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 87.73 · 95% CI 84.89 to 90.12VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 91.74 · 95% CI 86.25 to 95.37VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 92.57 · 95% CI 86.66 to 96.24VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 86.45 · 95% CI 82.98 to 89.33VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 84.33 · 95% CI 79.91 to 87.93VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One Confirmed HZ Case Over the Follow-up Years From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

A suspected case of HZ is defined as a new unilateral rash accompanied by pain and no alternative diagnosis. A confirmed case of HZ was diagnosed by PCR and/or by the HZAC determination, as per the algorithm pre-specified in the protocol. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies. Confirmed HZ cases data was not collected for the participants included in the HZ/su and Placebo/Historical control groups during Year 5, as this was a gap year between end of ZOSTER-006/-022 studies and start of ZOSTER-049:EXT-006-022 study. Results from the ZOSTER-006/022 studies were pooled for each year after vaccination with methods used in these studies. For overlapping years between ZOSTER-006/022 studies and this study, all the data were pooled. For the non-overlapping years only the data from ZOSTER-049:EXT 006-022 study was used.

Time frame:
Over the follow-up years (Year 1, Year 2, Year 3, Year 4, Year 6, Year 7, Year 8, Year 9, Year 10 and Year 11) from one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72)
Reported as:
Count of participants · Participants
Number of Participants Having at Least One Confirmed HZ Case Over the Follow-up Years From One Month Post-Dose 2 in ZOSTER-006/022 Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
ParticipantsHZ/su >=50 YOA GroupHZ/su 50-59 YOA GroupHZ/su 60-69 YOA GroupHZ/su >=60 YOA GroupHZ/su >=70 YOA GroupPlacebo/Historical Control >=50 YOA GroupPlacebo/Historical Control 50-59 YOA GroupPlacebo/Historical Control 60-69 YOA GroupPlacebo/Historical Control >= 60 YOA GroupPlacebo/Historical Control >=70 YOA Group
Year 13102213031169983
Year 2102187136272210987
Year 39009911629298758
Year 41012979516237956
Year 61021876216134735
Year 71012976115134633
Year 81022865815134331
Year 915531075715114229
Year 10150115145315103827
Year 11920775015103425
Statistical analysis
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 97.68 · 95% CI 93.07 to 99.53VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 96.76 · 95% CI 80.57 to 99.92VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 79.32 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 97.97 · 95% CI 92.46 to 99.76VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 97.57 · 95% CI 90.96 to 99.71VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 92.69 · 95% CI 86.15 to 96.57VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 92.66 · 95% CI 70.78 to 99.15VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 95.49 · 95% CI 72.11 to 99.89VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 92.71 · 95% CI 85.13 to 96.93VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 92.01 · 95% CI 82.82 to 96.88VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 92.36 · 95% CI 84.98 to 96.59VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 89.20 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 89.39 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 89.84 · 95% CI 79.81 to 95.51VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 84.74 · 95% CI 68.99 to 93.35VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 89.75 · 95% CI 80.31 to 95.24VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 93.88 · 95% CI 60.62 to 99.85VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 91.62 · 95% CI 66.10 to 99.04VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 88.96 · 95% CI 77.96 to 95.13VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 87.86 · 95% CI 73.30 to 95.33VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 83.87 · 95% CI 68.31 to 92.63VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 87.50 · 95% CI 46.83 to 98.61VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 92.31 · 95% CI 48.79 to 99.82VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 82.98 · 95% CI 63.64 to 93.05VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 80.00 · 95% CI 54.30 to 92.50VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 83.61 · 95% CI 67.76 to 92.51VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 93.33 · 95% CI 56.67 to 99.84VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 84.62 · 95% CI 32.04 to 98.31VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 80.43 · 95% CI 59.54 to 91.58VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 78.79 · 95% CI 51.24 to 92.08VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 82.76 · 95% CI 65.98 to 92.14VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 86.67 · 95% CI 42.67 to 98.52VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 84.62 · 95% CI 32.04 to 98.31VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 81.40 · 95% CI 59.97 to 92.45VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 80.65 · 95% CI 52.91 to 93.40VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 73.68 · 95% CI 52.89 to 86.16VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 66.67 · 95% CI 3.52 to 90.52VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 72.73 · 95% CI -3.24 to 95.11VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 76.19 · 95% CI 51.78 to 89.35VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 75.86 · 95% CI 43.69 to 91.07VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 71.70 · 95% CI 49.03 to 85.18VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 77.89 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 90.00 · 95% CI 29.71 to 99.77VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 60.53 · 95% CI 26.55 to 79.83VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 48.15 · 95% CI -2.41 to 74.87VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 82.00 · 95% CI 63.03 to 92.22VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 86.67 · 95% CI 42.67 to 98.52VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 65.07 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 79.41 · 95% CI 52.82 to 92.30VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 72.00 · 95% CI 33.41 to 89.77VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One Post-herpetic Neuralgia (PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Reported as:
Count of participants · Participants
Number of Participants Having at Least One Post-herpetic Neuralgia (PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
ParticipantsLTFU+Control >=50 YOA GroupLTFU+Control 50-59 YOA GroupLTFU+Control 60-69 YOA GroupLTFU+Control >=60 YOA GroupLTFU+Control >=70 YOA GroupHistorical Control >=50 YOA GroupHistorical Control 50-59 YOA GroupHistorical Control 60-69 YOA GroupHistorical Control >=60 YOA GroupHistorical Control >=70 YOA Group
Number of Participants Having at Least One Post-herpetic Neuralgia (PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges4014332722523
Statistical analysis
  • LTFU+Control >=50 YOA Group vs Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 87.50 · 95% CI 64.75 to 96.79VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control \>=50 YOA Group over Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • LTFU+Control 50-59 YOA Group vs Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 46.59 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control 50-59 YOA Group over Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • LTFU+Control 60-69 YOA Group vs Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 50.00 · 95% CI -860.45 to 99.15VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control 60-69 YOA Group over Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • LTFU+Control >=60 YOA Group vs Historical Control >=60 YOA Group · Poisson regression method · Vaccine efficacy: 84.00 · 95% CI 53.66 to 95.95VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control \>=60 YOA Group over Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • LTFU+Control >=70 YOA Group vs Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 86.96 · 95% CI 56.83 to 97.49VE = 1 - RR. RR = the ratio of the incidence rates of LTFU+Control \>=70 YOA Group over Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One PHN Case From One Month Post-Dose 2 in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

PHN is defined by the presence of HZ-associated severe worst pain persisting or appearing more than 90 days after onset of the HZ rash. Severe worst pain is defined as HZ-associated pain rated as 3 or greater on the worst pain question on the Zoster Brief Pain Inventory (ZBPI) questionnaire. The ZBPI questionnaire uses a 0 to 10 point numeric and visual intensity scale, in which 0 represents the minimum value and 10 the maximum value on the scale. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years
Reported as:
Count of participants · Participants
Number of Participants Having at Least One PHN Case From One Month Post-Dose 2 in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
ParticipantsHZ/su >=50 YOA GroupHZ/su 50-59 YOA GroupHZ/su 60-69 YOA GroupHZ/su >=60 YOA GroupHZ/su >=70 YOA GroupPlacebo/Historical Control >=50 YOA GroupPlacebo/Historical Control 50-59 YOA GroupPlacebo/Historical Control 60-69 YOA GroupPlacebo/Historical Control >= 60 YOA GroupPlacebo/Historical Control >=70 YOA Group
Number of Participants Having at Least One PHN Case From One Month Post-Dose 2 in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges80187781546359
Statistical analysis
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 89.69 · 95% CI 78.67 to 95.70VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 77.79 to 100.00VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 50-59 YOA Group over Placebo/Historical Control 50-59 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 74.75 · 95% CI -155.17 to 99.49VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su 60-69 YOA Group over Placebo/Historical Control 60-69 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 87.24 · 95% CI 73.29 to 94.72VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 88.08 · 95% CI 73.87 to 95.41VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against PHN in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One HZ Related Complications (Other Than PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Reported as:
Count of participants · Participants
Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
ParticipantsLTFU+Control >=50 YOA GroupLTFU+Control 50-59 YOA GroupLTFU+Control 60-69 YOA GroupLTFU+Control >=60 YOA GroupLTFU+Control >=70 YOA GroupHistorical Control >=50 YOA GroupHistorical Control 50-59 YOA GroupHistorical Control 60-69 YOA GroupHistorical Control >=60 YOA GroupHistorical Control >=70 YOA Group
Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges100111202119
Statistical analysis
  • LTFU+Control >=50 YOA Group vs Historical Control >=50 YOA Group · Poisson regression method · Vaccine efficacy: 91.67 · 95% CI 43.68 to 99.81VE=1-RR. RR=the ratio of the incidence rates of LTFU+Control \>=50 YOA Group over Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • LTFU+Control 60-69 YOA Group vs Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI -247.21 to 100.00VE=1-RR. RR=the ratio of the incidence rates of LTFU+Control 60-69YOA Group over Historical Control 60-69YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • LTFU+Control >=60 YOA Group vs Historical Control >=60 YOA Group · Poisson regression method · Vaccine efficacy: 90.91 · 95% CI 37.45 to 99.79VE=1-RR. RR=the ratio of the incidence rates of LTFU+Control \>=60YOA Group over Historical Control \>=60YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • LTFU+Control >=70 YOA Group vs Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 88.89 · 95% CI 19.81 to 99.75VE=1-RR. RR=the ratio of the incidence rates of LTFU+Control \>=70YOA Group over Historical Control \>=70YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
SecondaryNumber of Participants Having at Least One HZ Related Complications (Other Than PHN) Case From One Month Post-dose 2 (Month 3) in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges

HZ complications include HZ vasculitis, disseminated disease, ophthalmic disease, neurologic disease, visceral disease or stroke. If a recorded complication was associated with a case of suspected HZ, and that case was finally not considered to be a confirmed case, the associated complication would not be considered as a complication of HZ. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
From one month post-Dose 2 (Month 3) in ZOSTER-006/022 primary studies until the end of ZOSTER-049:EXT 006-022 study (Month 72), a period of approximately 12 years
Reported as:
Count of participants · Participants
Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case From One Month Post-dose 2 (Month 3) in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges
ParticipantsHZ/su >=50 YOA GroupHZ/su 50-59 YOA GroupHZ/su 60-69 YOA GroupHZ/su >=60 YOA GroupHZ/su >=70 YOA GroupPlacebo/Historical Control >= 50 YOA GroupPlacebo/Historical Control 50-59 YOA GroupPlacebo/Historical Control 60-69 YOA GroupPlacebo/Historical Control >= 60 YOA GroupPlacebo/Historical Control >=70 YOA Group
Number of Participants Having at Least One HZ Related Complications (Other Than PHN) Case From One Month Post-dose 2 (Month 3) in ZOSTER-006/022 Primary Studies Until the End of ZOSTER-049:EXT 006-022 Study, Overall and by Age Ranges2002228152621
Statistical analysis
  • HZ/su >=50 YOA Group vs Placebo/Historical Control >= 50 YOA Group · Poisson regression method · Vaccine efficacy: 92.83 · 95% CI 71.57 to 99.17VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=50 YOA Group over Placebo/Historical Control \>=50 YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • HZ/su 50-59 YOA Group vs Placebo/Historical Control 50-59 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI -1830.98 to 100.00VE=1-RR. RR=the ratio of the incidence rates of HZ/su 50-59YOA Group over Placebo/Historical Control 50-59YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • HZ/su 60-69 YOA Group vs Placebo/Historical Control 60-69 YOA Group · Poisson regression method · Vaccine efficacy: 100.00 · 95% CI 17.55 to 100.00VE=1-RR. RR=the ratio of the incidence rates of HZ/su 60-69YOA Group over Placebo/Historical Control 60-69YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • HZ/su >=60 YOA Group vs Placebo/Historical Control >= 60 YOA Group · Poisson regression method · Vaccine efficacy: 92.28 · 95% CI 69.17 to 99.11VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=60 YOA Group over Placebo/Historical Control \>=60 YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
  • HZ/su >=70 YOA Group vs Placebo/Historical Control >=70 YOA Group · Poisson regression method · Vaccine efficacy: 90.45 · 95% CI 60.93 to 98.91VE = 1 - RR. RR = the ratio of the incidence rates of HZ/su \>=70 YOA Group over Placebo/Historical Control \>=70 YOA Group. The VE of HZ/su vaccine against HZ related complications in this study was descriptively summarized by age strata and overall.
SecondaryAnti-glycoprotein (gE) Antibody Concentrations for Humoral Immunity (HI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group

Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs) in milli-international units per milliliter (mIU/mL). The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies
Reported as:
Geometric mean · mIU/mL
Anti-glycoprotein (gE) Antibody Concentrations for Humoral Immunity (HI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group
mIU/mLLTFU >=50 YOA GroupLTFU 50-59 YOA GroupLTFU 60-69 YOA GroupLTFU >=60 YOA GroupLTFU >=70 YOA Group
Year 58043.5 (7224.9 to 8954.7)8044.2 (6106.6 to 10596.6)8715.1 (6807.0 to 11158.1)8043.2 (7180.7 to 9009.3)7868.7 (6915.4 to 8953.5)
Year 68536.6 (8113.5 to 8981.7)8584.3 (7739.9 to 9520.7)8913.4 (8155.1 to 9742.3)8518.3 (8036.5 to 9028.9)8258.7 (7646.0 to 8920.4)
Year 78375.1 (7941.0 to 8833.0)8325.6 (7483.0 to 9263.1)8869.6 (8084.4 to 9731.1)8394.8 (7895.3 to 8925.8)8080.4 (7446.1 to 8768.7)
Year 88231.2 (7778.2 to 8710.6)8318.0 (7412.7 to 9333.9)8680.0 (7901.2 to 9535.5)8195.4 (7683.4 to 8741.5)7856.6 (7193.3 to 8581.0)
Year 97219.4 (6803.4 to 7660.9)7097.6 (6341.6 to 7943.7)7706.7 (6994.6 to 8491.4)7275.0 (6784.2 to 7801.3)6951.3 (6295.8 to 7674.9)
Year 106861.5 (6433.2 to 7318.3)7007.0 (6228.4 to 7882.9)7060.8 (6304.2 to 7908.3)6792.5 (6288.2 to 7337.3)6574.4 (5913.8 to 7308.8)
Year 117039.3 (6589.0 to 7520.5)7146.9 (6294.9 to 8114.3)7159.8 (6406.3 to 8001.9)6989.2 (6470.8 to 7549.2)6846.3 (6148.5 to 7623.3)
Year 126844.3 (6335.2 to 7394.3)6737.1 (5900.9 to 7691.7)6943.4 (6071.3 to 7940.7)6902.0 (6272.0 to 7595.3)6848.2 (5976.0 to 7847.6)
SecondaryFrequency of Antigen-specific CD4 (2+) T-cells for Cell Mediated Immunity (CMI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group

Frequency of CD4 (2+) T-cells with antigen-specific Interferon gamma (IFN-γ) and/or Interleukin-2 (IL-2) and/or Tumour Necrosis Factor alpha (TNF-α) and/or CD40 Ligand (CD40L) secretion/expression to gE was determined by Intracellular Cytokine Staining (ICS) and expressed in CD4 (2+) T-cells/million cells. The age ranges assessed were: \>=50 YOA (overall), 50-59 YOA, 60-69 YOA, \>=60 YOA and \>=70 YOA at time of primary vaccination in ZOSTER-006/022 studies.

Time frame:
At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies
Reported as:
Mean · CD4 (2+) T-cells/million cells
Frequency of Antigen-specific CD4 (2+) T-cells for Cell Mediated Immunity (CMI) Subset at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies, Overall and by Age Ranges in the LTFU Group
CD4 (2+) T-cells/million cellsLTFU >=50 YOA GroupLTFU 50-59 YOA GroupLTFU 60-69 YOA GroupLTFU >=60 YOA GroupLTFU >=70 YOA Group
Year 5698.00 ± 531.11858.92 ± 639.37—376.16 ± NA376.16 ± NA
Year 6886.15 ± 869.091174.70 ± 1103.76839.31 ± 644.97701.66 ± 621.26474.23 ± 515.96
Year 7859.46 ± 881.801141.00 ± 1074.96745.36 ± 572.57679.46 ± 683.15577.87 ± 828.60
Year 8896.26 ± 925.581217.84 ± 1155.53737.78 ± 602.91697.96 ± 688.76629.18 ± 827.35
Year 91099.20 ± 1151.151403.78 ± 1435.49930.89 ± 796.20892.09 ± 865.29801.54 ± 1033.67
Year 101016.13 ± 992.381210.28 ± 1216.92952.86 ± 763.05865.13 ± 755.35670.87 ± 726.96
Year 11909.95 ± 1025.401113.90 ± 1317.91884.65 ± 712.45753.74 ± 703.75445.15 ± 597.48
Year 12853.77 ± 815.201030.37 ± 971.86828.62 ± 666.18715.95 ± 647.90443.65 ± 531.44
SecondaryAnti-gE Antibody Concentrations for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies

Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

Time frame:
At Years 5, 6, 7, 8, 9, 10, 11 and 12 after the primary vaccination in ZOSTER-006/022 studies
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9, 10, 11 and 12 After the Primary Vaccination in ZOSTER-006/022 Studies
mIU/mLLTFU+Control >=50 YOA Group
Year 512455.1 (8549.9 to 18144.1)
Year 68138.7 (5770.6 to 11478.7)
Year 76888.0 (4919.2 to 9644.7)
Year 85831.9 (4435.1 to 7668.6)
Year 97706.8 (5941.6 to 9996.5)
Year 106800.1 (5048.6 to 9159.2)
Year 116214.7 (4807.3 to 8034.2)
Year 124770.7 (3523.6 to 6459.2)
SecondaryFrequency of Antigen-specific CD4 (2+) T-cells for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9 and 10 After the Primary Vaccination in ZOSTER-006/022 Studies

Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

Time frame:
At Years 5, 6, 7, 8, 9, and 10 after the primary vaccination in ZOSTER-006/022 studies
Reported as:
Mean · CD4 (2+) T-cells/million cells
Frequency of Antigen-specific CD4 (2+) T-cells for Participants in LTFU+Control >=50 YOA Group (With a Confirmed HZ Episode) at Years 5, 6, 7, 8, 9 and 10 After the Primary Vaccination in ZOSTER-006/022 Studies
CD4 (2+) T-cells/million cellsLTFU+Control >=50 YOA Group
Year 5683.76 ± NA
Year 6398.70 ± 164.34
Year 7347.43 ± 138.41
Year 8509.67 ± NA
Year 10749.75 ± NA
SecondaryAnti-gE Antibody Concentrations for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study

Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

Time frame:
At Month 1 in the current ZOSTER-049:EXT 006-022 study
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study
mIU/mL1-Additional Dose GroupRevaccination GroupControl Group
Anti-gE Antibody Concentrations for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study73834.4 (60603.6 to 89953.7)79419.8 (65089.6 to 96904.9)9655.2 (8316.9 to 11208.8)
SecondaryFrequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study

Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

Time frame:
At Month 1 in the current ZOSTER-049:EXT 006-022 study
Reported as:
Mean · CD4 (2+) T-cells/million cells
Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study
CD4 (2+) T-cells/million cells1-Additional Dose GroupRevaccination GroupControl Group
Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 1 in the Current ZOSTER-049:EXT 006-022 Study3899.69 ± 3243.162803.96 ± 1544.14716.01 ± 635.32
SecondaryAnti-gE Antibody Concentrations for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study

Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

Time frame:
At Month 3 in the current ZOSTER-049:EXT 006-022 study
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study
mIU/mLRevaccination GroupControl Group
Anti-gE Antibody Concentrations for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study64603.0 (54008.4 to 77275.9)9428.1 (8154.4 to 10900.8)
SecondaryFrequency of Antigen-specific CD4 (2+) T-cells for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study

Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

Time frame:
At Month 3 in the current ZOSTER-049:EXT 006-022 study
Reported as:
Mean · CD4 (2+) T-cells/million cells
Frequency of Antigen-specific CD4 (2+) T-cells for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study
CD4 (2+) T-cells/million cellsRevaccination GroupControl Group
Frequency of Antigen-specific CD4 (2+) T-cells for Revaccination and Control Groups at Month 3 in the Current ZOSTER-049:EXT 006-022 Study2443.17 ± 3896.14739.07 ± 659.78
SecondaryAnti-gE Antibody Concentrations for 1 Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study

Anti-gE antibody concentrations were determined by ELISA and expressed as GMCs in mIU/mL.

Time frame:
At Month 0 and Years 1, 2, 3, 4, 5 and 6 in the current ZOSTER-049:EXT 006-022 study
Reported as:
Geometric mean · mIU/mL
Anti-gE Antibody Concentrations for 1 Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study
mIU/mL1-Additional Dose GroupRevaccination GroupControl Group
Month 010149.5 (8640.2 to 11922.4)11548.5 (9386.8 to 14208.0)10232.0 (8836.7 to 11847.5)
Year 124663.6 (20790.2 to 29258.7)26167.5 (21755.6 to 31474.2)8825.4 (7616.3 to 10226.5)
Year 219417.9 (16460.7 to 22906.4)19973.2 (16538.1 to 24121.8)8643.3 (7450.5 to 10027.0)
Year 316335.6 (13890.4 to 19211.3)16264.7 (13417.7 to 19715.7)8314.9 (7080.3 to 9764.7)
Year 418676.4 (15562.0 to 22414.2)16363.2 (13219.3 to 20254.9)8581.7 (7195.2 to 10235.3)
Year 514797.3 (12340.7 to 17742.9)14595.7 (11767.0 to 18104.4)7238.7 (6004.3 to 8727.0)
Year 612868.4 (11048.3 to 14988.2)13534.0 (11107.7 to 16490.2)6858.8 (5698.0 to 8256.3)
SecondaryFrequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study

Frequency of CD4 (2+) T-cells with antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L secretion/expression to gE was determined by ICS and expressed in CD4 (2+) T-cells/million cells.

Time frame:
At Month 0 and Years 1, 2, 3, 4, 5 and 6 in the current ZOSTER-049:EXT 006-022 study
Reported as:
Mean · CD4(2+) T-cells/million cells
Frequency of Antigen-specific CD4(2+) T-cells for 1-Additional Dose, Revaccination and Control Groups at Month 0 and Years 1, 2, 3, 4, 5 and 6 in the Current ZOSTER-049:EXT 006-022 Study
CD4(2+) T-cells/million cells1-Additional Dose GroupRevaccination GroupControl Group
Month 0843.55 ± 792.93876.23 ± 784.84817.97 ± 809.77
Year 11798.39 ± 2119.461155.04 ± 714.97665.50 ± 603.93
Year 21634.47 ± 1900.931154.97 ± 818.16712.02 ± 715.32
Year 32112.90 ± 2564.291219.13 ± 889.76836.62 ± 921.57
Year 42047.92 ± 2477.921083.64 ± 669.54901.57 ± 917.41
Year 51649.03 ± 2407.72917.93 ± 648.92720.32 ± 726.20
Year 61682.94 ± 2694.90844.81 ± 651.28736.01 ± 724.10
SecondaryNumber of Participants With Any and Grade 3 Solicited Local Symptoms

The assessed solicited local symptoms included pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Reported as:
Count of participants · Participants
Number of Participants With Any and Grade 3 Solicited Local Symptoms
Participants1-Additional Dose GroupRevaccination Group
Any pain, post-Dose 14252
Grade 3 pain, post-Dose 113
Any redness, post-Dose 11320
Grade 3 redness, post-Dose 141
Any swelling, post-Dose 1712
Grade 3 swelling, post-Dose 110
Any pain, post-Dose 2—37
Grade 3 pain, post-Dose 2—2
Any redness, post-Dose 2—20
Grade 3 redness, post-Dose 2—3
Any swelling, post-Dose 2—13
Grade 3 swelling, post-Dose 2—1
SecondaryDuration in Days of Solicited Local Symptoms

Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited local symptoms included pain, redness and swelling.

Time frame:
Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Reported as:
Median · Days
Duration in Days of Solicited Local Symptoms
Days1-Additional Dose GroupRevaccination Group
Pain, post-Dose 13.0 (2.0 to 3.0)3.0 (2.0 to 3.5)
Pain, post-Dose 2—2.0 (2.0 to 3.0)
Redness, post-Dose 13.0 (2.0 to 4.0)3.0 (2.0 to 4.0)
Redness, post-Dose 2—2.5 (1.0 to 4.5)
Swelling, post-Dose 12.0 (2.0 to 3.0)3.0 (1.0 to 5.0)
Swelling, post-Dose 2—2.0 (1.0 to 3.0)
SecondaryNumber of Participants With Any, Grade 3 and Related Solicited General Symptoms

The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5 degrees Celsius (°C)\], gastrointestinal symptoms, headache, myalgia, and shivering. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \>39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Reported as:
Count of participants · Participants
Number of Participants With Any, Grade 3 and Related Solicited General Symptoms
Participants1-Additional Dose GroupRevaccination Group
Any fatigue, post-Dose 13224
Grade 3 fatigue, post-Dose 102
Related fatigue, post-Dose 13223
Any fever, post-Dose 11813
Grade 3 fever, post-Dose 100
Related fever, post-Dose 11813
Any gastrointestinal symptoms, post-Dose 199
Grade 3 gastrointestinal symptoms, post-Dose 102
Related gastrointestinal symptoms, post-Dose 198
Any headache, post-Dose 12317
Grade 3 headache, post-Dose 102
Related headache, post-Dose 12317
Any myalgia, post-Dose 12722
Grade 3 myalgia, post-Dose 102
Related myalgia, post-Dose 12721
Any shivering, post-Dose 12515
Grade 3 shivering, post-Dose 124
Related shivering, post-Dose 12515
Any fatigue, post-Dose 2—22
Grade 3 fatigue, post-Dose 2—3
Related fatigue, post-Dose 2—21
Any fever, post-Dose 2—7
Grade 3 fever, post-Dose 2—0
Related fever, post-Dose 2—4
Any gastrointestinal symptoms, post-Dose 2—4
Grade 3 gastrointestinal symptoms, post-Dose 2—0
Related gastrointestinal symptoms, post-dose 2—4
Any headache, post-Dose 2—15
Grade 3 headache, post-Dose 2—1
Related headache, post-Dose 2—14
Any myalgia, post-Dose 2—12
Grade 3 myalgia, post-Dose 2—1
Related myalgia, post-Dose 2—11
Any shivering, post-Dose 2—7
Grade 3 shivering, post-Dose 2—0
Related shivering, post-Dose 2—7
SecondaryDuration in Days of Solicited General Symptoms

Duration is the number of days in which a participant experienced the symptom within the 7-day solicited follow-up period. The assessed solicited general symptoms included fatigue, fever \[defined as oral temperature \>=37.5°C\], gastrointestinal symptoms, headache, myalgia, and shivering.

Time frame:
Within 7 days after each vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Reported as:
Median · Days
Duration in Days of Solicited General Symptoms
Days1-Additional Dose GroupRevaccination Group
Fatigue, post-Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 2.0)
Fatigue, post-Dose 2—2.0 (1.0 to 3.0)
Fever, post-Dose 11.0 (1.0 to 1.0)1.0 (1.0 to 2.0)
Fever, post-Dose 2—1.0 (1.0 to 2.0)
Gastrointestinal symptoms, post-Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 3.0)
Gastrointestinal symptoms, post-Dose 2—1.5 (1.0 to 2.0)
Headache, post-Dose 11.0 (1.0 to 2.0)2.0 (1.0 to 3.0)
Headache, post-Dose 2—2.0 (1.0 to 3.0)
Myalgia, post-Dose 12.0 (1.0 to 2.0)1.0 (1.0 to 3.0)
Myalgia, post-Dose 2—1.5 (1.0 to 2.5)
Shivering, post-Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Shivering, post-Dose 2—1.0 (1.0 to 2.0)
SecondaryNumber of Participants With Any Unsolicited Adverse Events (AEs)

An unsolicited AE is defined as any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
Within 30 days after any vaccination (vaccination occurring at Month 0 for 1-Additional Dose Group and at Months 0 and 2 for Revaccination Group) in the current ZOSTER-049:EXT 006-022 study
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited Adverse Events (AEs)
Participants1-Additional Dose GroupRevaccination Group
Number of Participants With Any Unsolicited Adverse Events (AEs)1315
SecondaryNumber of Participants With Any and Related Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant. Any SAE = occurrence of the SAE regardless of intensity or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to vaccination.

Time frame:
From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month 0 until 12 months after last HZ/su vaccination (Revaccination group)
Reported as:
Count of participants · Participants
Number of Participants With Any and Related Serious Adverse Events (SAEs)
Participants1-Additional Dose GroupRevaccination GroupControl Group
Any SAEs4411
Related SAEs000
SecondaryNumber of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant.

Time frame:
During the total duration of ZOSTER-049:EXT 006-022 study (from Month 0 to Month 72)
Reported as:
Count of participants · Participants
Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine
ParticipantsLTFU Group1-Additional Dose GroupRevaccination GroupControl Group
Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine0000
SecondaryNumber of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)

pIMDs are defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any pIMDs = occurrence of a pIMD regardless of relation to vaccination. Related pIMD = a pIMD assessed by the investigator as related to the study vaccination.

Time frame:
From Month 0 to Month 12 (1-Additional Dose and Control groups) and from Month until 12 months after last HZ/su vaccination (Revaccination group)
Reported as:
Count of participants · Participants
Number of Participants With Any and Related Potential Immune-mediated Diseases (pIMDs)
Participants1-Additional Dose GroupRevaccination GroupControl Group
Any pIMDs000
Related pIMDs000

Adverse events

Collected over Solicited AEs: Within 7 days after any vaccination & Unsolicited AEs: Within 30 days after any vaccination in this study. All-cause mortality & SAEs related to investigational vaccine/study participation/GSK concomitant medication/vaccine: during the entire study period (Month 0 to Month 72) (all study groups). All SAEs: Month 0 to Month 12 (1-Additional Dose & Control groups) and Month 0 until 12 months after last HZ/su vaccination (Revaccination group).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LTFU Group56/7,289 (0.8%)62/7,289 (0.9%)—
1-Additional Dose Group0/61 (0%)4/61 (6.6%)54/61 (88.5%)
Revaccination Group0/60 (0%)4/60 (6.7%)58/60 (96.7%)
Control Group0/119 (0%)11/119 (9.2%)—
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventLTFU Group1-Additional Dose GroupRevaccination GroupControl Group
SyncopeNervous system disorders0/72890/611/602/119
Myocardial infarctionCardiac disorders1/72890/611/600/119
Cardiac failure chronicCardiac disorders0/72890/611/600/119
DiverticulitisInfections and infestations0/72890/611/601/119
Mantle cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/72890/611/600/119
Metastases to peritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/72890/611/600/119
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/72890/611/600/119
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/72890/611/600/119
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/72890/611/600/119
SepsisInfections and infestations1/72891/610/600/119
Most frequent other events
Showing 10 of 33
Most frequent other events
EventLTFU Group1-Additional Dose GroupRevaccination GroupControl Group
PainGeneral disorders—42/6153/60—
FatigueGeneral disorders—32/6133/60—
ErythemaSkin and subcutaneous tissue disorders—13/6128/60—
MyalgiaMusculoskeletal and connective tissue disorders—27/6126/60—
ChillsGeneral disorders—26/6119/60—
HeadacheNervous system disorders—24/6123/60—
PyrexiaGeneral disorders—18/6117/60—
SwellingGeneral disorders—7/6116/60—
Gastrointestinal disorderGastrointestinal disorders—9/6110/60—
Oral herpesInfections and infestations—0/612/60—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LTFU Group1-Additional Dose GroupRevaccination GroupControl GroupTotal
Mean72.6 ± 9.470.4 ± 9.270.2 ± 9.470.2 ± 8.672.5 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)LTFU Group1-Additional Dose GroupRevaccination GroupControl GroupTotal
Female44323036694567
Male28573124502962
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LTFU Group1-Additional Dose GroupRevaccination GroupControl GroupTotal
African Heritage / African American6600066
Asian - East Asian Heritage11150001115
Asian - Japanese Heritage265000265
Other, Deidentified584361601196083
08

Study locations

161 sites
  • GSK Investigational Site
    Phoenix, Arizona 29651, United States
  • GSK Investigational Site
    Phoenix, Arizona 84123, United States
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Phoenix, Arizona 85306, United States
  • GSK Investigational Site
    Spring Valley, California 91978, United States
  • GSK Investigational Site
    Hallandale, Florida 85213, United States
  • GSK Investigational Site
    Boise, Idaho 83712, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Cary, North Carolina 27518, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28412, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Wadsworth, Ohio 44281, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2522, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Belo Horizonte, 30150-320, Brazil
  • GSK Investigational Site
    Curitiba, 80069-900, Brazil
  • GSK Investigational Site
    CuritibaPR, 80240-000, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    São Paulo, 04312903, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3M9, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4S 1Y2, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Woodstock, Ontario N4V 0E1, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y1W2, Canada
  • GSK Investigational Site
    Montreal, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Québec, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Québec, Quebec G1W 4R4, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    Brno, 612 00, Czechia
  • GSK Investigational Site
    České Budějovice, 370 05, Czechia
  • GSK Investigational Site
    Hradec Králové, 500 05, Czechia
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Pori, 28100, Finland
  • GSK Investigational Site
    Seinäjoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Angers, 49100, France
  • GSK Investigational Site
    Château-Gontier, 53200, France
  • GSK Investigational Site
    Clermont-Ferrand, 63003, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Montrevault, 49110, France
  • GSK Investigational Site
    Muret, 31600, France
  • GSK Investigational Site
    Mûrs-Erigné, 49610, France
  • GSK Investigational Site
    Nantes, 44300, France
  • GSK Investigational Site
    Rosiers-d'Égletons, 19300, France
  • GSK Investigational Site
    Segré, 49500, France
  • GSK Investigational Site
    Tours, 37100, France
  • GSK Investigational Site
    Berlin, 10629, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 13347, Germany
  • GSK Investigational Site
    Cologne, 51069, Germany
  • GSK Investigational Site
    Dachau, 85221, Germany
  • GSK Investigational Site
    Dresden, 01097, Germany
  • GSK Investigational Site
    Essen, 45355, Germany
  • GSK Investigational Site
    Essen, 45359, Germany
  • GSK Investigational Site
    Flörsheim, 65439, Germany
  • GSK Investigational Site
    Freiberg, 09599, Germany
  • GSK Investigational Site
    Goch, 47574, Germany
  • GSK Investigational Site
    Güglingen, 74363, Germany
  • GSK Investigational Site
    Hamburg, 20251, Germany
  • GSK Investigational Site
    Hamburg, 22143, Germany
  • GSK Investigational Site
    Hamburg, 22415, Germany
  • GSK Investigational Site
    Köthen, 06366, Germany
  • GSK Investigational Site
    Künzing, 94550, Germany
  • GSK Investigational Site
    Leipzig, 04315, Germany
  • GSK Investigational Site
    Lübeck, 23554, Germany
  • GSK Investigational Site
    Magdeburg, 39112, Germany
  • GSK Investigational Site
    Mainz, 55116, Germany
  • GSK Investigational Site
    Mannheim, 68161, Germany
  • GSK Investigational Site
    München, 80339, Germany
  • GSK Investigational Site
    Rednitzhembach, 91126, Germany
  • GSK Investigational Site
    Rhaunen, 55624, Germany
  • GSK Investigational Site
    Tübingen, 72074, Germany
  • GSK Investigational Site
    Wallerfing, 94574, Germany

Showing the first 100 of 161 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Strezova A, Diez Domingo J, Cunningham AL, Eto T, Andrews C, Arns C, Choo EJ, Hui DSC, Icardi G, McNeil SA, Poder A, Kosina P, Rombo L, Schwarz TF, Tinoco JC, Yu CJ, Wang J, Soni J, Tsang M, Leon R, Mwakingwe-Omari A; Zoster-049 Study Group. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. EClinicalMedicine. 2025 May 9;83:103241. doi: 10.1016/j.eclinm.2025.103241. eCollection 2025 May. PubMed 40630610 ↗
  • Leon R, Diez-Domingo J, Andrews C, Arns da Cunha C, Choo EJ, Hui DSC, Cunningham AL, Eto T, Icardi G, McNeil SA, Poder A, Kosina P, Rombo L, Schwarz TF, Tinoco JC, Yu CJ, Wang J, Soni J, Tsang M, Strezova A, Salaun B, Mwakingwe-Omari A. Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults >/=50 Years. Open Forum Infect Dis. 2026 May 4;13(6):ofag282. doi: 10.1093/ofid/ofag282. eCollection 2026 Jun. PubMed 42245229 ↗
  • Giannelos N, Curran D, Matthews S, Carrico J, Cunningham AL. The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide. Infect Dis Ther. 2025 Jun;14(6):1327-1341. doi: 10.1007/s40121-025-01161-y. Epub 2025 May 21. PubMed 40399558 ↗
  • Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, Choo EJ, Curiac D, Di Paolo E, Dionne M, Eckermann T, Esen M, Ferguson M, Ghesquiere W, Hwang SJ, Avelino-Silva TJ, Kosina P, Liu CS, Markkula J, Moeckesch B, Murta de Oliveira C, Park DW, Pauksens K, Pirrotta P, Plassmann G, Pretswell C, Rombo L, Salaun B, Sanmartin Berglund J, Schenkenberger I, Schwarz T, Shi M, Ukkonen B, Zahaf T, Zerbini C, Schuind A, Cunningham AL; Zoster-049 Study Group. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022 Apr 28;74(8):1459-1467. doi: 10.1093/cid/ciab629. PubMed 34283213 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jun 2023, 86 months.

Results were first posted in Sep 2024, 1 year 2 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 86 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2016
First posted
Mar 30, 2016
StartActual
Apr 16, 2016
Primary completionActual
Jun 28, 2023
CompletionActual
Jan 30, 2024
Results first posted
Sep 19, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02723773
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Apr 16, 2016
Primary completion
Jun 28, 2023
Completion
Jan 30, 2024
Results posted
Sep 19, 2024
Last update
Dec 12, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion